144 related articles for article (PubMed ID: 37480994)
1. Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.
Liu J; Zhang B; Su Y; Qin G; Kong X; Mo Y; Zhang R; Jiang W
Radiother Oncol; 2023 Oct; 187():109815. PubMed ID: 37480994
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer.
Wang MH; Vos LJ; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Ghosh S; Field C; Fallone BG; Murtha AD
Pract Radiat Oncol; 2021; 11(5):384-393. PubMed ID: 33705985
[TBL] [Abstract][Full Text] [Related]
3. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
Donaldson SS; Meza J; Breneman JC; Crist WM; Laurie F; Qualman SJ; Wharam M;
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):718-28. PubMed ID: 11597814
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.
Wang SL; Fang H; Hu C; Song YW; Wang WH; Jin J; Liu YP; Ren H; Liu J; Li GF; Du XH; Tang Y; Jing H; Ma YC; Huang Z; Chen B; Tang Y; Li N; Lu NN; Qi SN; Yang Y; Sun GY; Liu XF; Li YX
J Clin Oncol; 2020 Nov; 38(31):3604-3614. PubMed ID: 32780661
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer.
Tovanabutra C; Katanyoo K; Uber P; Chomprasert K; Sukauichai S
Asian Pac J Cancer Prev; 2020 Jan; 21(1):119-125. PubMed ID: 31983173
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP
Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003
[TBL] [Abstract][Full Text] [Related]
7. Comparative retrospective analysis of locoregional recurrence in unselected breast cancer patients treated with conventional versus hypofractionated radiotherapy at a tertiary cancer center?
Yadav R; Lal P; Agarwal S; Misra S; Verma M; Das KJM; Senthil Kumar SK; Kumar A; Mishra SK; Agarwal A; Agarwal G; Mishra A; Chand G; Verma AK; Kumar S
J Cancer Res Ther; 2020; 16(6):1314-1322. PubMed ID: 33342790
[TBL] [Abstract][Full Text] [Related]
8. Is There a Role for Hypofractionated Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer? A Propensity Score Matched Analysis.
Zayed S; Chen H; Ali E; Rodrigues GB; Warner A; Palma DA; Louie AV
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):575-586. PubMed ID: 32544575
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China.
Zhong QZ; Xia X; Gao H; Xu YG; Zhao T; Wu QH; Wang D; Lin HL; Sha XY; Liu M; Li GF
Aging (Albany NY); 2021 Feb; 13(5):6936-6944. PubMed ID: 33653964
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
You R; Liu YP; Huang PY; Zou X; Sun R; He YX; Wu YS; Shen GP; Zhang HD; Duan CY; Tan SH; Cao JY; Li JB; Xie YL; Zhang YN; Wang ZQ; Yang Q; Lin M; Jiang R; Zhang MX; Hua YJ; Tang LQ; Zhuang AH; Chen QY; Guo L; Mo HY; Chen Y; Mai HQ; Ling L; Liu Q; Chua MLK; Chen MY
JAMA Oncol; 2020 Sep; 6(9):1345-1352. PubMed ID: 32701129
[TBL] [Abstract][Full Text] [Related]
11. Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study.
Wang R; Wu F; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
J Cancer Res Clin Oncol; 2013 Jan; 139(1):139-45. PubMed ID: 22986812
[TBL] [Abstract][Full Text] [Related]
12. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials.
Lehrer EJ; Kishan AU; Yu JB; Trifiletti DM; Showalter TN; Ellis R; Zaorsky NG
Radiother Oncol; 2020 Jul; 148():235-242. PubMed ID: 32505965
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma.
Lyu J; Liu T; Li T; Li F; Wang Q; Wang J; Han Y; Wang J; Zhang J; Peng L; Lang J
Cancer Med; 2019 Jul; 8(8):3710-3718. PubMed ID: 31119872
[TBL] [Abstract][Full Text] [Related]
14. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer.
Saeed NA; Jin L; Amini A; Verma V; Lester-Coll NH; Chen PH; Decker RH; Park HS
Am J Clin Oncol; 2023 Feb; 46(2):66-72. PubMed ID: 36662872
[TBL] [Abstract][Full Text] [Related]
15. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
20. Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017).
Chen N; Li Q; Wang S; Xiong M; Luo Y; Wang B; Chen L; Lin M; Jiang X; Fang J; Guo S; Guo J; Hu N; Ai X; Wang D; Chu C; Liu F; Long H; Wang J; Qiu B; Liu H
Lung Cancer; 2021 Jun; 156():82-90. PubMed ID: 33933895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
